Drugs for Vulvovaginal Candidiasis Market Report – Research, Industry Analysis Reports and Market Demands

Global Drugs for Vulvovaginal Candidiasis Market Insights, Forecast to 2025

Request for Sample of this report

Buy now

Table of Content

1 Study Coverage

1.1 Drugs for Vulvovaginal Candidiasis Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
- 1.4.1 Global Drugs for Vulvovaginal Candidiasis Market Size Growth Rate by Product
- 1.4.2 Cream
- 1.4.3 Pessary
- 1.4.4 Other
1.5 Market by End User
- 1.5.1 Global Drugs for Vulvovaginal Candidiasis Market Size Growth Rate by End User
- 1.5.2 Hospital & Clinic
- 1.5.3 Pharmacy
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary

2.1 Global Drugs for Vulvovaginal Candidiasis Market Size
- 2.1.1 Global Drugs for Vulvovaginal Candidiasis Revenue 2014-2025
- 2.1.2 Global Drugs for Vulvovaginal Candidiasis Sales 2014-2025
2.2 Drugs for Vulvovaginal Candidiasis Growth Rate by Regions
- 2.2.1 Global Drugs for Vulvovaginal Candidiasis Sales by Regions
- 2.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Regions

3 Breakdown Data by Manufacturers

3.1 Drugs for Vulvovaginal Candidiasis Sales by Manufacturers
- 3.1.1 Drugs for Vulvovaginal Candidiasis Sales by Manufacturers
- 3.1.2 Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturers
- 3.1.3 Global Drugs for Vulvovaginal Candidiasis Market Concentration Ratio (CR5 and HHI)
3.2 Drugs for Vulvovaginal Candidiasis Revenue by Manufacturers
- 3.2.1 Drugs for Vulvovaginal Candidiasis Revenue by Manufacturers (2014-2019)
- 3.2.2 Drugs for Vulvovaginal Candidiasis Revenue Share by Manufacturers (2014-2019)
3.3 Drugs for Vulvovaginal Candidiasis Price by Manufacturers
3.4 Drugs for Vulvovaginal Candidiasis Manufacturing Base Distribution, Product Types
- 3.4.1 Drugs for Vulvovaginal Candidiasis Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Drugs for Vulvovaginal Candidiasis Product Type
- 3.4.3 Date of International Manufacturers Enter into Drugs for Vulvovaginal Candidiasis Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

4.1 Global Drugs for Vulvovaginal Candidiasis Sales by Product
4.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Product
4.3 Drugs for Vulvovaginal Candidiasis Price by Product

5 Breakdown Data by End User

5.1 Overview
5.2 Global Drugs for Vulvovaginal Candidiasis Breakdown Data by End User

6 North America

6.1 North America Drugs for Vulvovaginal Candidiasis by Countries
- 6.1.1 North America Drugs for Vulvovaginal Candidiasis Sales by Countries
- 6.1.2 North America Drugs for Vulvovaginal Candidiasis Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
6.2 North America Drugs for Vulvovaginal Candidiasis by Product
6.3 North America Drugs for Vulvovaginal Candidiasis by End User

7 Europe

7.1 Europe Drugs for Vulvovaginal Candidiasis by Countries
- 7.1.1 Europe Drugs for Vulvovaginal Candidiasis Sales by Countries
- 7.1.2 Europe Drugs for Vulvovaginal Candidiasis Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
7.2 Europe Drugs for Vulvovaginal Candidiasis by Product
7.3 Europe Drugs for Vulvovaginal Candidiasis by End User

8 Asia Pacific

8.1 Asia Pacific Drugs for Vulvovaginal Candidiasis by Countries
- 8.1.1 Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Countries
- 8.1.2 Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
8.2 Asia Pacific Drugs for Vulvovaginal Candidiasis by Product
8.3 Asia Pacific Drugs for Vulvovaginal Candidiasis by End User

9 Central & South America

9.1 Central & South America Drugs for Vulvovaginal Candidiasis by Countries
- 9.1.1 Central & South America Drugs for Vulvovaginal Candidiasis Sales by Countries
- 9.1.2 Central & South America Drugs for Vulvovaginal Candidiasis Revenue by Countries
- 9.1.3 Brazil
9.2 Central & South America Drugs for Vulvovaginal Candidiasis by Product
9.3 Central & South America Drugs for Vulvovaginal Candidiasis by End User

10 Middle East and Africa

10.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis by Countries
- 10.1.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Countries
- 10.1.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
10.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis by Product
10.3 Middle East and Africa Drugs for Vulvovaginal Candidiasis by End User

11 Company Profiles

12 Future Forecast

12.1 Drugs for Vulvovaginal Candidiasis Market Forecast by Regions
- 12.1.1 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Regions 2019-2025
- 12.1.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Regions 2019-2025
12.2 Drugs for Vulvovaginal Candidiasis Market Forecast by Product
- 12.2.1 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Product 2019-2025
- 12.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Product 2019-2025
12.3 Drugs for Vulvovaginal Candidiasis Market Forecast by End User
12.4 North America Drugs for Vulvovaginal Candidiasis Forecast
12.5 Europe Drugs for Vulvovaginal Candidiasis Forecast
12.6 Asia Pacific Drugs for Vulvovaginal Candidiasis Forecast
12.7 Central & South America Drugs for Vulvovaginal Candidiasis Forecast
12.8 Middle East and Africa Drugs for Vulvovaginal Candidiasis Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

14.1 Value Chain Analysis
14.2 Drugs for Vulvovaginal Candidiasis Customers
14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
16.2 Author Details

Description

The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.
The classification of Drugs for Vulvovaginal Candidiasis includes Cream, Pessary and other. The proportion of Cream in 2017 is about 47.2%, and the proportion of Pessary in 2017 is about 34.1%.
The drugs for Vulvovaginal Candidiasis are Miconazole, Clotrimazole, Fluconazole, Econazole and Other, market share of Fluconazole is about 24.5% in 2017.
Drugs for Vulvovaginal Candidiasis is application in Hospital & Clinic and Pharmacy. The most of Drugs for Vulvovaginal Candidiasis is used in Pharmacy, and the market share in 2016 is about 59%.
The global Drugs for Vulvovaginal Candidiasis market is valued at 770 million US$ in 2018 and will reach 860 million US$ by the end of 2025, growing at a CAGR of 1.5% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Drugs for Vulvovaginal Candidiasis market based on company, product type, end user and key regions.

This report studies the global market size of Drugs for Vulvovaginal Candidiasis in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Drugs for Vulvovaginal Candidiasis in these regions.
This research report categorizes the global Drugs for Vulvovaginal Candidiasis market by top players/brands, region, type and end user. This report also studies the global Drugs for Vulvovaginal Candidiasis market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group

Market size by Product
By Formulation Types
Cream
Pessary
Other
By Drugs Types
Miconazole
Clotrimazole
Fluconazole
Econazole
Other
Market size by End User
Hospital & Clinic
Pharmacy

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Drugs for Vulvovaginal Candidiasis market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Drugs for Vulvovaginal Candidiasis market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Drugs for Vulvovaginal Candidiasis companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Drugs for Vulvovaginal Candidiasis submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Drugs for Vulvovaginal Candidiasis are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Drugs for Vulvovaginal Candidiasis market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.